Literature DB >> 1313906

Driving adenovirus type 12-transformed BALB/c mouse cells to express high levels of class I major histocompatibility complex proteins enhances, rather than abrogates, their tumorigenicity.

S Soddu1, A M Lewis.   

Abstract

The tumorigenicity of adenovirus type 12 (Ad12)-transformed cells has been attributed to the low levels of class I major histocompatibility complex (MHC) protein expression by these cells. These levels of class I proteins are thought to be below the threshold critical for cytotoxic T-lymphocyte recognition, a process that may be involved in tumor cell immunosurveillance. We have used gene transfer experiments to investigate the role played by class I protein expression in the tumorigenicity of Ad12-transformed BALB/c mouse cells in naive, syngeneic adult mice. Our Ad12-transformed mouse cells were tumorigenic in adult mice and were similar to other Ad12-transformed mammalian cells in that they expressed low levels of class I MHC mRNA and cell surface proteins. Despite these low levels of expression, the cells were highly immunogenic in syngeneic mice and were rejected as allografts by allogeneic mice. Transfection of genomic H-2Dd or H-2Ld fragments into these cells produced a variety of cell clones that expressed increased levels of cell surface class I proteins. These cells expressing high levels of class I protein were up to 16-fold more tumorigenic than the parental cells in syngeneic adult mice. Thus, by quantitative assays, the tumorigenicity of Ad12-transformed BALB/c mouse cells is not functionally related to the low levels of class I MHC proteins they express. The increased tumorigenicity expressed by H-2Dd- and H-2Ld-transfected cells was not detected in BALB/c nu/nu mice, suggesting that a thymus-dependent mechanism that is not mediated by evasion of cytotoxic T-lymphocyte recognition could contribute to the difference in tumorigenicity of Ad12-transformed BALB/c mouse cells that express low and high levels of class I MHC proteins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313906      PMCID: PMC241046     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Nuclear proteins binding to an enhancer element of the major histocompatibility class I promoter: differences between highly oncogenic and nononcogenic adenovirus-transformed rat cells.

Authors:  A M Ackrill; G E Blair
Journal:  Virology       Date:  1989-10       Impact factor: 3.616

2.  Tumour production in immunosuppressed rats with cells transformed in vitro by adenovirus type 2.

Authors:  P H Gallimore
Journal:  J Gen Virol       Date:  1972-07       Impact factor: 3.891

3.  Increased tumour induction by adenovirus type 12 in thymectomized mice and mice treated with anti-lymphocyte serum.

Authors:  A C Allison; L D Berman; R H Levey
Journal:  Nature       Date:  1967-07-08       Impact factor: 49.962

4.  YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage.

Authors:  G E Piontek; K Taniguchi; H G Ljunggren; A Grönberg; R Kiessling; G Klein; K Kärre
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

5.  CD3-negative lymphokine-activated cytotoxic cells express the CD3 epsilon gene.

Authors:  R Biassoni; S Ferrini; I Prigione; A Moretta; E O Long
Journal:  J Immunol       Date:  1988-03-01       Impact factor: 5.422

6.  Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene.

Authors:  K Tanaka; K J Isselbacher; G Khoury; G Jay
Journal:  Science       Date:  1985-04-05       Impact factor: 47.728

7.  Tumorigenicity of adenovirus-transformed cells: collagen interaction and cell surface laminin are controlled by the serotype origin of the E1A and E1B genes.

Authors:  F J Bober; D E Birk; T Shenk; K Raska
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

8.  Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells.

Authors:  K Tanaka; H Hayashi; C Hamada; G Khoury; G Jay
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

9.  Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines.

Authors:  L A Lampson; C A Fisher; J P Whelan
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

10.  Histocompatibility antigens on murine tumors.

Authors:  R S Goodenow; J M Vogel; R L Linsk
Journal:  Science       Date:  1985-11-15       Impact factor: 47.728

View more
  3 in total

1.  Tumorigenicity of adenovirus-transformed rodent cells is influenced by at least two regions of adenovirus type 12 early region 1A.

Authors:  T Jelinek; D S Pereira; F L Graham
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

2.  Constructing chimeric type 12/type 5 adenovirus E1A genes and using them to identify an oncogenic determinant of adenovirus type 12.

Authors:  G C Telling; J Williams
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

3.  Transfected lymphocyte extracts of patients with urological tumours: complement temperature-sensitive adenovirus mutants in vitro.

Authors:  J Ongrádi; S Csata; J Farkas; I Nász; M Bendinelli
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.